الفهرس 
Breast Cancer
Previous chest radiationOnly 14 pages are availabe for public view
 |  | from | 204 |  |  |
| | | from | 204 | | |
Abstract
This study was done at Medical Biochemistry Department, Faculty of Medicine, Ain Sham University and included 42 patients and 12 normal volunteers.
The aim of the current study was to evaluate the expression of lnRNA-ESRG & lncRNA-HAGLR in malignant, benign breast lesions and healthy normal individuals (after breast reduction surgery) by RT-PCR and to correlate the expression of both lncRNAs with the various clinico-pathological parameters in an attempt to evaluate the role of lncRNA-ESRG & lncRNA-HAGLR in tumor assessment and to explore their synergistic expression and their use as potential selected diagnostic marker in breast cancer.
The studied individuals were classified into three main groups:
group A, including 30 malignant breast cancer patients with median age 56 years.
group B, including12 benign breast lesion patients with median age 52.5 years.group C, including 12 Healthy normal individuals with median age 54.5 years.
All patients in the present study were subjected to complete detailed history taking, general and local examination, routine laboratory investigations and radiological examinations. Also all patients were subjected to detection of ER, PR Her2/neu screening by immunohistochemistry.
The breast tumor was resected and sent for pathological staging (according to TNM classification) and grading. Evaluation of lncRNA-ESRG & lncRNA-HAGLR expression in sera (54) and breast tissue samples (12) was performed by RT-PCR in relation to GAPDH as the housekeeping gene in all samples.
Then the results were calculated and statistically analyzed by the SPSS software.
A significant difference was observed in the sensitivity of lncRNA-ESRG & lncRNA-HAGLR of sera samples of the malignant group i.e. (83.3% and 73.3%) as compared with both benign group (0% and 8.3%) and healthy normal group (0% and 8.3%) respectively (P< 0.01).
Applying 0.73 and 1.045 as a cut off value; which was calculated by ROC curve, the lncRNA-ESRG & lncRNA-HAGLR showed (83.3% and 73.3%) sensitivity, (100% and 91.6%) specificity, (100% and 91.6%) PPV, (82.7% and 73.3%) NPV and (90.7% and 88.8%) accuracy.
Moreover, a significant difference was found between mean rank levels of lncRNA-ESRG & lncRNA-HAGLR of serum samples in malignant group i.e. (17.8 and 18.15) as compared with either benign breast condition group (39.5 and 37.75) or healthy normal group (39.67and 40.63) (P< 0.01).
No significant association between lncRNA-ESRG or lncRNA-HAGLR in sera samples is detected by quantitative RT-PCR and any of clinico-pathological factors including parity, menopause, family history, BMI, OCT, HRT, pathological type, stage and grade.
Finally, there was a strong positive correlation between serum and breast tissue lncRNA-ESRG & lncRNA-HAGLR (0.851& 0.816) with (p <0.01).